A detailed history of Bank Of America Corp transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 223 shares of UNCY stock, worth $93. This represents 0.0% of its overall portfolio holdings.

Number of Shares
223
Holding current value
$93
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.4 - $1.46 $89 - $325
223 New
223 $0
Q4 2022

Feb 10, 2023

BUY
$0.5 - $0.78 $5 - $7
10 New
10 $0
Q1 2022

May 16, 2022

SELL
$1.07 - $2.28 $22 - $47
-21 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$1.81 - $3.05 $38 - $64
21 New
21 $0

Others Institutions Holding UNCY

About Unicycive Therapeutics, Inc.


  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $6.32M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.